This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
CRTH2 Antagonist Program (Seelos)
Seelos Therapeutics, Inc.
Drug Names(s): CRTH2 Antagonist Program
Description: Seelos is developing a licensed CRTH2 antagonist program for the treatment of respiratory disorders.
Ligand and Seelos
In September 2016, Ligand Pharmaceuticals announced the licensing of rights to four programs to Seelos Therapeutics.The licensed therapeutic programs include Ligand's aplindore (now known as SLS-006) program for the treatment of various CNS disorders, a CRTH2 antagonist program for the treatment of respiratory disorders, a Captisol-enabled acetaminophen program for pain and fever management and an H3 receptor antagonist program for the treatment of narcolepsy.
Under the license agreement, Ligand is entitled to receive initial payments in equity or cash of $1.3 million upon Seelos completing a minimum of $7.5 million financing and up to an additional $3.5 million if Seelos becomes a public company and up to $145 million of additional cash milestones. In addition, Ligand is entitled to net sales royalties ranging from 4% to 10% for the various programs licensed. Ligand has also entered into a supply agreement for Captisol. If certain conditions are...See full deal structure in Biomedtracker
Partners: Ligand Pharmaceuticals, Inc.
CRTH2 Antagonist Program (Seelos) News
Additional information available to subscribers only: